TABLE 1.

In vitro activity of azole antifungal agents against 6,970 clinical isolates of Candida species stratified by fluconazole susceptibility

Antifungal agent	Fluconazole susceptibility categorya	No. tested	Cumulative % inhibited at MIC (μg/ml) of:
			0.12	0.25	0.5	1	2	4	8	16	32	64	>64
Fluconazole	All	6,970	15	54	68	75	80	85	90	95	97	98	100
	S	6,268	17	60	75	84	89	95	100	100	100	100	100
	S-DD	463	0	0	0	0	0	0	0	73	100	100	100
	R	239	0	0	0	0	0	0	0	0	0	44	100
Itraconazole	All	6,970	69	81	90	97	98	99	99
	S	6,268	77	89	96	99	99	100	100
	S-DD	463	2	12	33	77	95	98	99
	R	239	0	5	29	49	56	62	70
Voriconazole	All	6,970	87	93	96	98	99	99	99
	S	6,268	96	99	99	100	100	100	100
	S-DD	463	8	44	77	96	99	100	100
	R	239	0	10	36	52	71	80	86
Ravuconazole	All	6,970	85	91	96	98	99	99	99
	S	6,268	93	98	99	99	99	100	100
	S-DD	463	10	35	63	88	97	99	99
	R	239	12	27	49	58	69	80	86

^aS MIC, ≤8 μg/ml; S-DD MIC, 16 to 32 μg/ml; R MIC, ≥64 μg/ml.